Literature DB >> 1910648

Inpatient comprehensive rehabilitation after liver transplantation.

S M Tuel1, J M Meythaler, L L Cross.   

Abstract

Liver transplantation has become a standard treatment for liver failure and is covered by Medicare. Transplantation has up to an 80% survival rate; however, the postoperative course can include many complications, a long hospital admission and the need for the involvement of many medical and therapeutic disciplines. Ideally, this is provided by a coordinated comprehensive rehabilitation program, but descriptions of this type of management are absent from the literature. This report describes the case of a 54-yr-old male with alcoholic cirrhosis who underwent orthotopic liver transplantation. His postoperative course was complicated, and he developed global weakness secondary to hepatic neuropathy with superimposed type II steroid-induced myopathy. Four months after the transplant he was unable to sit up in bed and was admitted to the rehabilitation unit. The patient required two subsequent admissions to the acute hospital for complications; however, close cooperation between the surgical transplant team and the rehabilitation team facilitated functional improvement and enabled discharge to home in less than 8 wk. At discharge, the patient was independent in bed mobility, transfers and self-care, and he was ambulating with contact guard. Medical issues, including evaluation, medications and possible complications in the rehabilitative phase are discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1910648     DOI: 10.1097/00002060-199110000-00003

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  1 in total

1.  Comparative study of the effect of neuromuscular electrical stimulation and oral administration of branched-chain amino acid on preventing sarcopenia in patients after living-donor liver transplantation: study protocol for an open-label randomized controlled trial.

Authors:  Masafumi Haraguchi; Kunihiro Ichinose; Hisamitsu Miyaaki; Masatoshi Hanada; Masanori Fukushima; Ryu Sasaki; Satoshi Miuma; Takanobu Hara; Tota Kugiyama; Akihiko Soyama; Masaaki Hidaka; Ayumi Tsuji; Rintaro Yano; Motohiro Sekino; Hideaki Takahata; Susumu Eguchi; Kazuhiko Nakao
Journal:  Trials       Date:  2021-02-12       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.